Biotech Companies — Annual Report Financials

The most directly comparable table in the catalogue: commercial-stage biotechs close on the same calendar date, disclose R&D without exception, and file under recognisable revenue tags. That makes the ratio of research spend to revenue meaningful here in a way it is not elsewhere. The caveat is survivorship — these are companies with approved products and real revenue, so the table says nothing about the far larger population of clinical-stage firms with no revenue to report.

Every company in this table closes its financial year on the same date, so the rows describe the same twelve months and are directly comparable on timing. All 6 disclose research and development separately, which makes research intensity comparable across the whole table. Figures were retrieved from EDGAR on 2026-07-25.

Each row is taken from that company's latest annual report (Form 10-K) as filed with the U.S. Securities and Exchange Commission, read through EDGAR's structured XBRL data. The “Source filing” column links the exact submission, so any cell can be checked against the original in one click. Fiscal years differ by company — each row states its own fiscal-year end rather than pretending the sector shares one calendar.

This table is regenerated from EDGAR by a versioned script, not edited by hand; the retrieval date is printed above the table. The underlying filing data is U.S. government work in the public domain; viewing, sorting, charting, downloading, and embedding this compilation requires a free VIDANALYTICA account. Company selection is a size-and-coverage editorial choice among U.S.-listed 10-K filers in the sector, not a ranking, rating, or recommendation of any company.

These are the reported baselines — the questions that decide strategy (share shifts, pricing models, segment growth, what the filings say beneath the totals) are what our research briefs answer. Start with the Biotech research practice, or size the opportunity yourself with the market-size calculator.